{"count":57,"next":"https://lda.gov/api/v1/filings/?filing_specific_lobbying_issues=H.R.+832&filing_year=2026&ordering=-filing_year&page=2","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/1ace8877-2fc9-42a8-8d5a-abd7a5d6352e/","filing_uuid":"1ace8877-2fc9-42a8-8d5a-abd7a5d6352e","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/1ace8877-2fc9-42a8-8d5a-abd7a5d6352e/print/","filing_document_content_type":"text/html","income":null,"expenses":"100382.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Noyan Eyigor","dt_posted":"2026-04-09T15:06:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1600 20TH STREET, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20009","registrant":{"id":32362,"url":"https://lda.gov/api/v1/registrants/32362/","house_registrant_id":32102,"name":"PUBLIC CITIZEN","description":null,"address_1":"1600 20TH STREET, NW","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20009","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NOYAN EYIGOR","contact_telephone":"+1 202-588-1000","dt_updated":"2026-07-09T13:18:42.426797-04:00"},"client":{"id":140490,"url":"https://lda.gov/api/v1/clients/140490/","client_id":12,"name":"PUBLIC CITIZEN","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-03"},"lobbying_activities":[{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"crypto legislation, credit card bills, small bank regulation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143538,"prefix":"mr","prefix_display":"MR.","first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"HOLMAN","suffix":"phd","suffix_display":"PHD"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CIV","general_issue_code_display":"Civil Rights/Civil Liberties","description":"Sen. Blumenthal re. Forced Arb/ Amtrak , Sen. Gillibrand re. Protecting Older Americans Act , Email Re. Fosters office re. Investor Choice Act , Forced Arbitration - Mass Arbitration , Roblox Article.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138383,"prefix":null,"prefix_display":null,"first_name":"MARTHA","nickname":null,"middle_name":null,"last_name":"PEREZ-PEDEMONTI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPI","general_issue_code_display":"Computer Industry","description":"AI Preemption Issue","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151739,"prefix":null,"prefix_display":null,"first_name":"JOSHUA","nickname":null,"middle_name":null,"last_name":"BRANCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CSP","general_issue_code_display":"Consumer Issues/Safety/Products","description":"SBA Office of Advocacy Deregulatory Initiative (Small Business Committee Minority Staff); Blast Oppo Email on HR 6622 to all House Judiciary Committee Member Staff; H.R. 6622 (Rep. Jayapal staff). H.R. 6544, Review Act of 2025; Regulatory reform meeting, H.J. Res. 140, Research on Office of Advocacy and Tariffs Shared with Senate and House Small Business Committee Staff (re DUMP Red Tape Act HR 4305),Standing Meeting with HSGAC Minority Staff (1.0); Draft Letter to Senate on H.J. Res. 140, Senator Klobuchar re. Product Safety , Meeting with HSGAC Minority Staff , EXPERTS Act , Rep. Lee Staff (EXPERTS Act, H.R. 6145; Dump Red Tape Act H.R. 4305, Midnight Rules Relief Act H.R. 77, Small Business Regulatory Reduction Act, H.R. 2965), Rep. Gottheimer (EXPERTS H.R. 6145), Rep. Min (EXPERTS H.R. 6145), Call with Jacob Press, Small Bus Minority, Supporting New Businesses Act (S. 1608), EXPERTS Act (HR 6145) Dump Red Tape Act (HR 4305), REINS Act (HR 142), Midnight Rules Relief Act )(HR 77) (Rep. Mcdonald Rivet), Standing Meeting with Senate HSGAC Staff (discussed independent agency reforms).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138628,"prefix":"ms","prefix_display":"MS.","first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"SKERRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151740,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"TRACY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138383,"prefix":null,"prefix_display":null,"first_name":"MARTHA","nickname":null,"middle_name":null,"last_name":"PEREZ-PEDEMONTI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Sen. Bennet Crypto Bill/Preemption , Communications opposing Public Company Advisory Committee Act (H.R. 6967). Communications supporting bill to oppose removal of elected DC Attorney General (H.R. 5179).,","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138383,"prefix":null,"prefix_display":null,"first_name":"MARTHA","nickname":null,"middle_name":null,"last_name":"PEREZ-PEDEMONTI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144141,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"GOLINGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"H.R.6622, Sunshine for Regulatory Decrees and Settlements Act\", Congressional stock trading ban (HR5106), Democratic leadership bill on stock trading by Congress and the executive branch (No number yet), Cap credit card late fees (No number yet), Honest Act (S1879), Restore Trust in Congress Act (HR 5106), Restore Trust in Government Act (HR6731), Supreme Court ethics and term limits (S1814), Congressional stock trading ban (HR5106, HR6731, HR7008), DISCLOSE Act of 2026 (No number yet), Expand personal financial disclosure requirements (No number yet), Johnson amendment on political activities by nonprofit organizations (No bill yet), DISCLOSE Act (No numbers yet), H.R. 6967, the Public Company Advisory Committee Act, Legislation to prevent government officials from enriching themselves through lawsuit settlements, Potential anti-corruption reforms, Prohibit congressional stock trading (HR5106, HR6731, HR7008), Prediction Markets insider trading by government officials (no number yet), SAVE Act (HR22) and SAVE 2.0 (No number yet), Supreme Court ethics and disclosure (HR3513, S1814), FOIA Clarification Act, congressional stock trading (HR 5106, 6731 and 7008); and on the Democratic House ethics package (No number yet), Ban political betting on prediction market platforms (No number yet),Congressional stock trading (HR5106, HR6731, HR7008), DISCLOSE Act (S3391,HR7802), End Congressional Stock Trading (HR 5106, HR6731, HR7008), End Prediction Markets Corruption Act (S4017),SAVE America Act (S3752, HR7296).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60196,"prefix":"ms","prefix_display":"MS.","first_name":"SUSAN","nickname":null,"middle_name":"ELAINE","last_name":"HARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143538,"prefix":"mr","prefix_display":"MR.","first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"HOLMAN","suffix":"phd","suffix_display":"PHD"},"covered_position":null,"new":false},{"lobbyist":{"id":144141,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":null,"last_name":"GOLINGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.3069 & S.1506 - Medicare for All","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66133,"prefix":null,"prefix_display":null,"first_name":"EAGAN","nickname":null,"middle_name":null,"last_name":"KEMP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Medicare drug price negotiation improvement and expansion; EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices; NDAA & public drug and API manufacturing,S.2276, H.R.3269 (ETHIC Act).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66542,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"KNIEVEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"POS","general_issue_code_display":"Postal","description":"opposing privatization of the USPS","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60196,"prefix":"ms","prefix_display":"MS.","first_name":"SUSAN","nickname":null,"middle_name":"ELAINE","last_name":"HARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Direct File Act of 2026, Disclosure of Tax Havens and Offshoring Act, Tax Excessive CEO Pay Act (S.2818/H.R. 5298), Curtailing Executive Overcompensation (CEO) Act (S. 3176/H.R. 6191), Billionaires Income Tax Act (S.2845/H.R.5427), Wall Street Tax Act (S.2127/H.R.4035), Equal Tax Act (H.R. 5336), AI tax issues, Ultra-Millionaire Tax Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60196,"prefix":"ms","prefix_display":"MS.","first_name":"SUSAN","nickname":null,"middle_name":"ELAINE","last_name":"HARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/9fb65ecc-d100-4763-bfdc-17860017431d/","filing_uuid":"9fb65ecc-d100-4763-bfdc-17860017431d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9fb65ecc-d100-4763-bfdc-17860017431d/print/","filing_document_content_type":"text/html","income":null,"expenses":"50973.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-04-10T12:57:08-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b61e96b2-3412-4795-9479-cc82759463cf/","filing_uuid":"b61e96b2-3412-4795-9479-cc82759463cf","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b61e96b2-3412-4795-9479-cc82759463cf/print/","filing_document_content_type":"text/html","income":null,"expenses":"130000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Heather Strawn","dt_posted":"2026-04-16T15:47:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Ave NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400426042,"url":"https://lda.gov/api/v1/registrants/400426042/","house_registrant_id":null,"name":"LUNDBECK LLC","description":"Specialty and Central Nervous System Bio-pharmaceutical manufacturing","address_1":"1455 Pennsylvania Ave NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"HEATHER STRAWN","contact_telephone":"+1 202-412-1563","dt_updated":"2026-07-29T13:14:27.156557-04:00"},"client":{"id":190625,"url":"https://lda.gov/api/v1/clients/190625/","client_id":12,"name":"LUNDBECK LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to Pharmacy Benefit Managers - H.R.4317, PBM Reform Act of 2025; H.R.6703, Lower Health Care Premiums for All Americans Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Reauthorization of the Pediatric Priority Review Voucher program at the FDA Issues related to DTC advertising regulations Pediatric rare diseases - H.R. 1262 & S. 932, Give Kids a Chance Act of 2025 Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues pertaining to the 340B Drug Discount Program - H.R. 5256, 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to Pharmacy Benefit Managers - S.3345, PBM Price Transparency and Accountability Act; H.R.4317, PBM Reform Act of 2025 Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariffs on pharmaceutical products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/83f32e55-db9b-4e18-a208-0ab012ae7526/","filing_uuid":"83f32e55-db9b-4e18-a208-0ab012ae7526","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/83f32e55-db9b-4e18-a208-0ab012ae7526/print/","filing_document_content_type":"text/html","income":"5250.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Karen R. Harned","dt_posted":"2026-04-18T12:30:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3713 N Edison St","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Arlington","registrant_state":"VA","registrant_zip":"22207","registrant":{"id":401107499,"url":"https://lda.gov/api/v1/registrants/401107499/","house_registrant_id":56038,"name":"HARNED STRATEGIES LLC","description":null,"address_1":"1506 Woodacre Drive","address_2":null,"address_3":null,"address_4":null,"city":"McLean","state":"VA","state_display":"Virginia","zip":"22101","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KAREN R HARNED","contact_telephone":"+1 202-886-4651","dt_updated":"2026-09-26T14:42:28.625406-04:00"},"client":{"id":55813,"url":"https://lda.gov/api/v1/clients/55813/","client_id":55813,"name":"JOB CREATORS NETWORK","general_description":"advocacy organization for small business","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-04"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support passage of H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Supported Mike Johnson for Speaker of the House. Support passage of H.R. 4178, the Enforce the Caps Act, which would extend federal spending caps through fiscal year 2029. Support H.R. 4, the Rescissions Act of 2025, which would help cut government spending. Support H.R. 3174, the Made in America Manufacturing Finance Act, which would expand access to credit for American manufacturers under the Small Business Administrations 7(a) and 504 loan program. Support H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, which provided a clean continuing resolution to extend funding through January 30, 2026, and also included full-year appropriations for several key departments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Support Federal Education Freedom Scholarships","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Support United States trade deals with China and the United Kingdom.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Supported S. 832, the Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025,\" bipartisan, bicameral legislation that fixes the Inflation Reduction Act's small molecule pill penalty to ensure continued R&D investments into small molecule medicines. Support H.R. 5256, 340B ACCESS Act to reform the 340B drug pricing program. Oppose extending the Affordable Care Act subsidies. Support H.R.6703 - Lower Health Care Premiums for All Americans Act designed to cut health costs by, among other things, expanding Association Health Plans (AHPs) for small businesses, creating new \"CHOICE\" arrangements for tax-free health spending, allowing stop-loss insurance for employers, increasing PBM transparency, and funding marketplace cost-sharing. Support President Trump's Great American Healthcare Plan.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SMB","general_issue_code_display":"Small Business","description":"Supported nomination of Kelly Loeffler to serve as Administrator of the Small Business Administration. Supported H.R. 1199/S.695, the Small Business Investment Act of 2025,\" which would dramatically increase private sector investment in American small businesses by rewarding investors for supporting small business. Supported S. 495 /H.R. 1163, the \"Prove It Act,\" which seeks to reduce burdensome regulations for small businesses by empowering them to petition federal agencies to review proposed regulations that impact small businesses.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Support extending the provisions in the 2017 Tax Cuts and Jobs Act, as set forth in H.R. 1, the \"One Big Beautiful Bill Act.\" Support additional reductions to small business tax rates.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"UNM","general_issue_code_display":"Unemployment","description":"Supported H.R. 1156 - the \"Pandemic Unemployment Fraud Enforcement Act,\" which would extend the statute of limitations for combatting and prosecuting the theft of COVID-era unemployment benefits, giving more time for law enforcement to complete current cases, open new ones and recoup billions of taxpayer dollars. Supported S. 4016, the \"Stop Unemployment Fraud Act,\" which would bolster the integrity in the unemployment insurance system by strengthening identify verification and fraud detection measures. Among other thigs it would require states to use advanced data matching and restrict benefit payments until applicant eligibility is confirmed.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Support H.R. 5371 - Continuing Appropriations and Extensions Act, 2026 Supported S. 100/H.R. 425, the Repealing Big Brother Overreach Act, which would repeal the Corporate Transparency Act. Support Small Business Investment Act as included in H.R. 1. Support reforms that would limit the ability of credit card companies to raise processing fees on small businesses who accept credit cards for payment. Support Investor Accelerator Executive Order to reduce much of the burdensome red tape that often prevents investors and entrepreneurs from making their projects a reality. Support the nomination of Kevin Warsh to serve as the Chairman of the Federal Reserve.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Supported S. 583/H.R. 1295 Reorganizing Government Act of 2025,\" which seeks to renew and extend the President's authority to propose executive branch reorganization plans until December 2026, for the purpose of modernizing and improve government efficiency. Supported Mike Johnson for Speaker of the House.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support Medicaid work requirements in H.R.1, \"One Big Beautiful Bill Act.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Support H.R. 6644, the Housing for the 21st Century Act, which would help boost housing supply and affordability by modernizing federal programs, streamlining regulations, and encouraging local innovation. Among other things it would update FHA loans, reform the HOME program, and support zoning reform, while aiming to reduce building costs and complexity for developers and local governments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Support H.R.5267 - American Franchise Act, which would clarify that franchisors are only joint employers if they possess and exercise substantial and immediate control over essential terms and conditions of employment, like hiring workers, firing workers, setting wages, and disciplinary action.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"Supported national food labeling standards","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b0e163ff-e4ab-4a78-8273-24ec2a8471d5/","filing_uuid":"b0e163ff-e4ab-4a78-8273-24ec2a8471d5","filing_type":"1A","filing_type_display":"1st Quarter - Amendment","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b0e163ff-e4ab-4a78-8273-24ec2a8471d5/print/","filing_document_content_type":"text/html","income":"5250.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Karen R. Harned","dt_posted":"2026-04-18T12:35:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1506 Woodacre Drive","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"McLean","registrant_state":"VA","registrant_zip":"22101","registrant":{"id":401107499,"url":"https://lda.gov/api/v1/registrants/401107499/","house_registrant_id":56038,"name":"HARNED STRATEGIES LLC","description":null,"address_1":"1506 Woodacre Drive","address_2":null,"address_3":null,"address_4":null,"city":"McLean","state":"VA","state_display":"Virginia","zip":"22101","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KAREN R HARNED","contact_telephone":"+1 202-886-4651","dt_updated":"2026-09-26T14:42:28.625406-04:00"},"client":{"id":55813,"url":"https://lda.gov/api/v1/clients/55813/","client_id":55813,"name":"JOB CREATORS NETWORK","general_description":"advocacy organization for small business","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-04"},"lobbying_activities":[{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Support H.R.5267 - American Franchise Act, which would clarify that franchisors are only joint employers if they possess and exercise substantial and immediate control over essential terms and conditions of employment, like hiring workers, firing workers, setting wages, and disciplinary action.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"Supported national food labeling standards","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support passage of H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Supported Mike Johnson for Speaker of the House. Support passage of H.R. 4178, the Enforce the Caps Act, which would extend federal spending caps through fiscal year 2029. Support H.R. 4, the Rescissions Act of 2025, which would help cut government spending. Support H.R. 3174, the Made in America Manufacturing Finance Act, which would expand access to credit for American manufacturers under the Small Business Administrations 7(a) and 504 loan program. Support H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, which provided a clean continuing resolution to extend funding through January 30, 2026, and also included full-year appropriations for several key departments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Support Federal Education Freedom Scholarships","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Supported S. 832, the Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025,\" bipartisan, bicameral legislation that fixes the Inflation Reduction Act's small molecule pill penalty to ensure continued R&D investments into small molecule medicines. Support H.R. 5256, 340B ACCESS Act to reform the 340B drug pricing program. Oppose extending the Affordable Care Act subsidies. Support H.R.6703 - Lower Health Care Premiums for All Americans Act designed to cut health costs by, among other things, expanding Association Health Plans (AHPs) for small businesses, creating new \"CHOICE\" arrangements for tax-free health spending, allowing stop-loss insurance for employers, increasing PBM transparency, and funding marketplace cost-sharing. Support President Trump's Great American Healthcare Plan.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SMB","general_issue_code_display":"Small Business","description":"Supported nomination of Kelly Loeffler to serve as Administrator of the Small Business Administration. Supported H.R. 1199/S.695, the Small Business Investment Act of 2025,\" which would dramatically increase private sector investment in American small businesses by rewarding investors for supporting small business. Supported S. 495 /H.R. 1163, the \"Prove It Act,\" which seeks to reduce burdensome regulations for small businesses by empowering them to petition federal agencies to review proposed regulations that impact small businesses.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Support extending the provisions in the 2017 Tax Cuts and Jobs Act, as set forth in H.R. 1, the \"One Big Beautiful Bill Act.\" Support additional reductions to small business tax rates.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"UNM","general_issue_code_display":"Unemployment","description":"Supported H.R. 1156 - the \"Pandemic Unemployment Fraud Enforcement Act,\" which would extend the statute of limitations for combatting and prosecuting the theft of COVID-era unemployment benefits, giving more time for law enforcement to complete current cases, open new ones and recoup billions of taxpayer dollars. Supported S. 4016, the \"Stop Unemployment Fraud Act,\" which would bolster the integrity in the unemployment insurance system by strengthening identify verification and fraud detection measures. Among other thigs it would require states to use advanced data matching and restrict benefit payments until applicant eligibility is confirmed.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Support H.R. 5371 - Continuing Appropriations and Extensions Act, 2026 Supported S. 100/H.R. 425, the Repealing Big Brother Overreach Act, which would repeal the Corporate Transparency Act. Support Small Business Investment Act as included in H.R. 1. Support reforms that would limit the ability of credit card companies to raise processing fees on small businesses who accept credit cards for payment. Support Investor Accelerator Executive Order to reduce much of the burdensome red tape that often prevents investors and entrepreneurs from making their projects a reality. Support the nomination of Kevin Warsh to serve as the Chairman of the Federal Reserve.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Supported S. 583/H.R. 1295 Reorganizing Government Act of 2025,\" which seeks to renew and extend the President's authority to propose executive branch reorganization plans until December 2026, for the purpose of modernizing and improve government efficiency. Supported Mike Johnson for Speaker of the House.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support Medicaid work requirements in H.R.1, \"One Big Beautiful Bill Act.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Support United States trade deals with China and the United Kingdom.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Support H.R. 6644, the Housing for the 21st Century Act, which would help boost housing supply and affordability by modernizing federal programs, streamlining regulations, and encouraging local innovation. Among other things it would update FHA loans, reform the HOME program, and support zoning reform, while aiming to reduce building costs and complexity for developers and local governments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/553731d7-b6b8-4798-a852-493fff671761/","filing_uuid":"553731d7-b6b8-4798-a852-493fff671761","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/553731d7-b6b8-4798-a852-493fff671761/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-04-18T15:56:32-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":196641,"url":"https://lda.gov/api/v1/clients/196641/","client_id":1356,"name":"NOVARTIS, INC.","general_description":"Multinational biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-03-26"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e741dba8-ef30-4b2b-9636-65ad775eeeb4/","filing_uuid":"e741dba8-ef30-4b2b-9636-65ad775eeeb4","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/e741dba8-ef30-4b2b-9636-65ad775eeeb4/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Minor, Partner","dt_posted":"2026-04-20T12:04:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 8th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":76855,"url":"https://lda.gov/api/v1/registrants/76855/","house_registrant_id":32113,"name":"DLA PIPER LLP (US)","description":"Law firm.","address_1":"500 8th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MINOR","contact_telephone":"+1 202-799-4312","dt_updated":"2026-07-30T08:35:35.415773-04:00"},"client":{"id":67264,"url":"https://lda.gov/api/v1/clients/67264/","client_id":67264,"name":"NOVARTIS","general_description":"Innovative medicines company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-05-01"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property protections and enforcement. Biopharmaceutical patent policy.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149501,"prefix":null,"prefix_display":null,"first_name":"VINCENT","nickname":null,"middle_name":null,"last_name":"SARUBBI","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax reform and tax policy.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149501,"prefix":null,"prefix_display":null,"first_name":"VINCENT","nickname":null,"middle_name":null,"last_name":"SARUBBI","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariffs.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149501,"prefix":null,"prefix_display":null,"first_name":"VINCENT","nickname":null,"middle_name":null,"last_name":"SARUBBI","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149501,"prefix":null,"prefix_display":null,"first_name":"VINCENT","nickname":null,"middle_name":null,"last_name":"SARUBBI","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142803,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SORENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149501,"prefix":null,"prefix_display":null,"first_name":"VINCENT","nickname":null,"middle_name":null,"last_name":"SARUBBI","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/1418a58b-0775-4e45-9b77-06e8109c2656/","filing_uuid":"1418a58b-0775-4e45-9b77-06e8109c2656","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/1418a58b-0775-4e45-9b77-06e8109c2656/print/","filing_document_content_type":"text/html","income":null,"expenses":"12210000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Paul J. Larsen","dt_posted":"2026-04-20T13:06:32-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Avenue, SW","registrant_address_2":"Suite 1000","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":31350,"url":"https://lda.gov/api/v1/registrants/31350/","house_registrant_id":30654,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","description":null,"address_1":"670 Maine Avenue, SW","address_2":"Suite 1000","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL J. LARSEN","contact_telephone":"+1 202-835-3400","dt_updated":"2026-07-30T11:08:37.463508-04:00"},"client":{"id":138226,"url":"https://lda.gov/api/v1/clients/138226/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law No. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law No. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law No. 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No. 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/dcd7521a-5037-4ae0-85ac-b59569500a8b/","filing_uuid":"dcd7521a-5037-4ae0-85ac-b59569500a8b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/dcd7521a-5037-4ae0-85ac-b59569500a8b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Isabella Quinn","dt_posted":"2026-04-20T13:48:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 Pennsylvania Avenue, NW","registrant_address_2":"Suite 800","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":41454,"url":"https://lda.gov/api/v1/registrants/41454/","house_registrant_id":30771,"name":"WILLIAMS AND JENSEN, PLLC","description":"Lobbying Law Firm","address_1":"1201 Pennsylvania Avenue, NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ISABELLA QUINN","contact_telephone":"+1 202-659-8201","dt_updated":"2026-07-30T10:41:36.640087-04:00"},"client":{"id":151176,"url":"https://lda.gov/api/v1/clients/151176/","client_id":645,"name":"PHRMA","general_description":"Represents country's leading pharmaceutical research and biotechnology companies","client_government_entity":false,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose \"most favored nation\" pricing on Medicare Part B and D. \"Inflation Reduction Act of 2022\" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, \"One Big Beautiful Bill Act\", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose \"most favored nation\" pricing on Medicare Part B and D. \"Inflation Reduction Act of 2022\" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to pharmaceutical manufacturing and development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"IP Protections related to trade agreements; trade policies impacting pharmaceutical development; potential tariff actions under Section 232 of the Trade Act of 1962. Legislative proposals related to WTO TRIPS Waiver.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/dcd7521a-5037-4ae0-85ac-b59569500a8b/","filing_uuid":"dcd7521a-5037-4ae0-85ac-b59569500a8b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/dcd7521a-5037-4ae0-85ac-b59569500a8b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Isabella Quinn","dt_posted":"2026-04-20T13:48:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 Pennsylvania Avenue, NW","registrant_address_2":"Suite 800","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":41454,"url":"https://lda.gov/api/v1/registrants/41454/","house_registrant_id":30771,"name":"WILLIAMS AND JENSEN, PLLC","description":"Lobbying Law Firm","address_1":"1201 Pennsylvania Avenue, NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ISABELLA QUINN","contact_telephone":"+1 202-659-8201","dt_updated":"2026-07-30T10:41:36.640087-04:00"},"client":{"id":151176,"url":"https://lda.gov/api/v1/clients/151176/","client_id":645,"name":"PHRMA","general_description":"Represents country's leading pharmaceutical research and biotechnology companies","client_government_entity":false,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose \"most favored nation\" pricing on Medicare Part B and D. \"Inflation Reduction Act of 2022\" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, \"One Big Beautiful Bill Act\", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose \"most favored nation\" pricing on Medicare Part B and D. \"Inflation Reduction Act of 2022\" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to pharmaceutical manufacturing and development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"IP Protections related to trade agreements; trade policies impacting pharmaceutical development; potential tariff actions under Section 232 of the Trade Act of 1962. Legislative proposals related to WTO TRIPS Waiver.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e8e7b414-e066-4ab6-a68c-95ef70ab621c/","filing_uuid":"e8e7b414-e066-4ab6-a68c-95ef70ab621c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/e8e7b414-e066-4ab6-a68c-95ef70ab621c/print/","filing_document_content_type":"text/html","income":null,"expenses":"600000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-04-20T13:55:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/23743058-dc9c-4c42-9e63-de465eff836c/","filing_uuid":"23743058-dc9c-4c42-9e63-de465eff836c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/23743058-dc9c-4c42-9e63-de465eff836c/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2026-04-20T15:13:30-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-10-07T16:33:47.376828-04:00"},"client":{"id":176429,"url":"https://lda.gov/api/v1/clients/176429/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":"Represents the leading research-based pharmaceutical companies in the US.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":"Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas","new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e3beff28-2272-4f88-b28c-e7fa63e13ebd/","filing_uuid":"e3beff28-2272-4f88-b28c-e7fa63e13ebd","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/e3beff28-2272-4f88-b28c-e7fa63e13ebd/print/","filing_document_content_type":"text/html","income":null,"expenses":"3510000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jane Adams","dt_posted":"2026-04-20T16:34:13-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"ONE JOHNSON & JOHNSON PLAZA","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"NEW BRUNSWICK","registrant_state":"NJ","registrant_zip":"08933","registrant":{"id":20686,"url":"https://lda.gov/api/v1/registrants/20686/","house_registrant_id":30348,"name":"JOHNSON & JOHNSON SERVICES, INC.","description":null,"address_1":"ONE JOHNSON & JOHNSON PLAZA","address_2":null,"address_3":null,"address_4":null,"city":"NEW BRUNSWICK","state":"NJ","state_display":"New Jersey","zip":"08933","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JANE ADAMS","contact_telephone":"+1 202-589-1000","dt_updated":"2026-07-30T18:01:40.268804-04:00"},"client":{"id":126906,"url":"https://lda.gov/api/v1/clients/126906/","client_id":12,"name":"JOHNSON & JOHNSON SERVICES INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions - H.R. 3514, the Improving Seniors Timely Access to Care Act of 2025, regarding all provisions - H.R. 6549, the VA Contracting and Procurement Act, regarding all provisions - H.R. 5509 / S. 2903, Safe Step Act, regarding all provisions - H.R. 5256, 340B ACCESS Act, regarding all provisions - H.R. 7391, Community Health Center Drug Pricing Protection Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B and 340B Rebate Pilot - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing - CMS Outpatient Prospective Payment System rule - peripheral artery disease (PAD) - PBM and Insurer Reforms","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":91402,"prefix":null,"prefix_display":null,"first_name":"DEANA","nickname":null,"middle_name":null,"last_name":"MCRAE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70499,"prefix":null,"prefix_display":null,"first_name":"LEIF","nickname":null,"middle_name":null,"last_name":"BRIERLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71075,"prefix":null,"prefix_display":null,"first_name":"LARRY","nickname":null,"middle_name":null,"last_name":"CAMM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141363,"prefix":null,"prefix_display":null,"first_name":"TIMOTHY","nickname":null,"middle_name":null,"last_name":"SWOPE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137136,"prefix":null,"prefix_display":null,"first_name":"WENDY","nickname":null,"middle_name":null,"last_name":"SUSSMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139147,"prefix":"mrs","prefix_display":"MRS.","first_name":"MEGHAN","nickname":null,"middle_name":"DRENAN","last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137135,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"PELLEGRINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70494,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"WATERS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73113,"prefix":null,"prefix_display":null,"first_name":"ABIGAIL","nickname":null,"middle_name":null,"last_name":"PINKELE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18909,"prefix":"mrs","prefix_display":"MRS.","first_name":"JANE","nickname":null,"middle_name":"MARGARET","last_name":"ADAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141364,"prefix":null,"prefix_display":null,"first_name":"COLLEEN","nickname":null,"middle_name":null,"last_name":"VIVALDI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":55206,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KAVANAUGH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150724,"prefix":null,"prefix_display":null,"first_name":"JULIA","nickname":null,"middle_name":null,"last_name":"KALUSNIAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153683,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"LAST","suffix":null,"suffix_display":null},"covered_position":"Sen. PA, Senate HELP Committee (2025); PA, Sen. Cornyn (2017-2022, 2023-2025); Sen. LA, Rep. Brady (2017); Sen. LA, Rep. Lance (2009-2012); LC/LA Rep. Knollenberg (2006-2008).","new":true},{"lobbyist":{"id":153684,"prefix":null,"prefix_display":null,"first_name":"FOLASHADE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":"Health Fellow, Office of Robin Kelly (Sept 2024-Sept 2025); Health Fellow, Office of Bernard Sanders (Sept 2024-Oct 2025).","new":true},{"lobbyist":{"id":153685,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"CLARKIN","suffix":null,"suffix_display":null},"covered_position":"Legislative Director for Rep. Brian Fitzpatrick (March 2025-January 2026)","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"- Issues related to stroke care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70499,"prefix":null,"prefix_display":null,"first_name":"LEIF","nickname":null,"middle_name":null,"last_name":"BRIERLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including amending the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55206,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KAVANAUGH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141363,"prefix":null,"prefix_display":null,"first_name":"TIMOTHY","nickname":null,"middle_name":null,"last_name":"SWOPE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137136,"prefix":null,"prefix_display":null,"first_name":"WENDY","nickname":null,"middle_name":null,"last_name":"SUSSMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":18909,"prefix":"mrs","prefix_display":"MRS.","first_name":"JANE","nickname":null,"middle_name":"MARGARET","last_name":"ADAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70494,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"WATERS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"- H.R. 2483, \"SUPPORT for Patients and Communities Reauthorization Act of 2025\", regarding all provisions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137135,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"PELLEGRINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137136,"prefix":null,"prefix_display":null,"first_name":"WENDY","nickname":null,"middle_name":null,"last_name":"SUSSMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Issues related to - artificial intelligence - data privacy - cybersecurity - robotics","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70499,"prefix":null,"prefix_display":null,"first_name":"LEIF","nickname":null,"middle_name":null,"last_name":"BRIERLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB and the corporate alternative minimum tax - use of excess pension funds","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55206,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KAVANAUGH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70494,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"WATERS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - military/veterans affairs health workforce and talent workforce","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":91402,"prefix":null,"prefix_display":null,"first_name":"DEANA","nickname":null,"middle_name":null,"last_name":"MCRAE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137136,"prefix":null,"prefix_display":null,"first_name":"WENDY","nickname":null,"middle_name":null,"last_name":"SUSSMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70499,"prefix":null,"prefix_display":null,"first_name":"LEIF","nickname":null,"middle_name":null,"last_name":"BRIERLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141364,"prefix":null,"prefix_display":null,"first_name":"COLLEEN","nickname":null,"middle_name":null,"last_name":"VIVALDI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"- Issues related to USMCA review and renegotiation","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55206,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KAVANAUGH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139147,"prefix":"mrs","prefix_display":"MRS.","first_name":"MEGHAN","nickname":null,"middle_name":"DRENAN","last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a229bfd0-5906-4e09-949f-3e2dab8d1b73/","filing_uuid":"a229bfd0-5906-4e09-949f-3e2dab8d1b73","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a229bfd0-5906-4e09-949f-3e2dab8d1b73/print/","filing_document_content_type":"text/html","income":null,"expenses":"2030000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Parrish","dt_posted":"2026-04-20T17:37:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 Pennsylvania Ave., NW Suite 900","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":5632,"url":"https://lda.gov/api/v1/registrants/5632/","house_registrant_id":31257,"name":"BAYER CORPORATION (CONSOLIDATED REPORT)","description":null,"address_1":"801 Pennsylvania Ave., NW Suite 900","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL PARRISH","contact_telephone":"+1 202-737-8900","dt_updated":"2026-07-30T15:08:38.983388-04:00"},"client":{"id":107401,"url":"https://lda.gov/api/v1/clients/107401/","client_id":12,"name":"BAYER CORPORATION (CONSOLIDATED REPORT)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Monitor and engage on legislative and administrative action related to Miscellaneous Tariff Bill (MTB) petitions. Monitor and engage on legislative and administrative action related to Section 301 tariffs. Monitor and engage on legislative and administrative action related to tariff deferment. Monitor and engage on legislative and administrative action related to tariff suspensions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to biofuels, including ethanol, the RFS, and sustainable aviation fuel. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill reauthorization. Monitor and engage on legislative and administrative action related to Ag chemistry. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21). H.R. 7567, Farm, Food and National Security Act of 2026, including Section 10205 -- Uniformity of Pesticide Labeling Requirements. S. 3122, Better Food Disclosure Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":15,"name":"Council on Environmental Quality (CEQ)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit. Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.Con.Res. 14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R. 4754, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026. H.R. 5371, Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R. 6938, Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026. S. 2431, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements, including purchasing through HSA funds. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Monitor and engage on legislative and administrative action related to trade. Monitor and engage on legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor and engage on legislative and administrative action related to China import approvals, and foreign direct investment prohibitions and restrictions. Monitor and engage in administrative action related to maximum residue levels (MRLs) in the ASEAN region. Monitor and engage on legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor and engage on legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor and engage on legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor and engage on legislative and administrative action related to intellectual property issues and regulations in India. Monitor and engage on legislative and administrative action related to World Trade Organization (WTO) digital trade rules. Monitor and engage on legislative and administrative action related to Section 301 tariffs. Monitor and engage on legislative and administrative action related to Section 232 tariffs. Monitor and engage on legislative and administrative action related to IEEPA tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":41,"name":"Treasury, Dept of"},{"id":196,"name":"U.S. Agency for International Development (USAID)"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"ENG","general_issue_code_display":"Energy/Nuclear","description":"Monitor and engage on legislative and administrative action related to Biofuels and the Renewable Fuel Standard. Monitor and engage on the implementation of the Infrastructure Investment and Jobs Act (P.L. 117-58). Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"NAT","general_issue_code_display":"Natural Resources","description":"Monitor and engage on legislative and administrative action related to phosphate mining operations and permits. Monitor and engage on legislative and administrative action related to Caldwell Canyon permitting. Monitor and engage on legislative and administrative action related to proposed Conservation and Landscape Health Rule and Greater Sage Grouse Habitat Conservation Plans. Monitor and engage on legislative and administrative action related to the Endangered Species Act. Monitor and engage regarding the inclusion of glyphosate on the critical minerals list. Monitor and engage on legislative and administrative action related to the Fairness and Certainty in Reclamation Act (no bill number yet). H.R. 1897, ESA Amendments Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":148,"name":"Bureau of Land Management (BLM)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":36,"name":"Interior, Dept of (DOI)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":144,"name":"U.S. Geological Survey (USGS)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Monitor and engage on legislative and administrative action related to climate change, including sustainable agriculture. Monitor and engage on legislative and administrative action related to FIFRA Regulations, including voluntary carbon markets. Monitor and engage on legislative and administrative action related to the Endangered Species Act. H.R. 1897, ESA Amendments Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Monitor and engage on legislative and administrative action related to antitrust and competition.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"Resolution expressing a commitment to strengthen science, technology, and innovation R&D for economic development in Africa, and the importance for US engagement with Africa to address global challenges.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/28ec0c34-6b95-468a-80c6-d2ada239917d/","filing_uuid":"28ec0c34-6b95-468a-80c6-d2ada239917d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/28ec0c34-6b95-468a-80c6-d2ada239917d/print/","filing_document_content_type":"text/html","income":null,"expenses":"820000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Terri Stewart, Senior Vice President, Head of Global Healthcare Government & Public Affairs","dt_posted":"2026-04-20T19:42:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1299 Pennsylvania Avenue, NW","registrant_address_2":"Suite 825","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":48736,"url":"https://lda.gov/api/v1/registrants/48736/","house_registrant_id":34558,"name":"EMD SERONO, INC.","description":null,"address_1":"1299 Pennsylvania Avenue, NW","address_2":"Suite 825","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TERRI STEWART","contact_telephone":"+1 415-389-6800","dt_updated":"2026-07-30T19:36:40.951348-04:00"},"client":{"id":155478,"url":"https://lda.gov/api/v1/clients/155478/","client_id":12,"name":"EMD SERONO INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.R.5256: 340B ACCESS Act; all provisions General discussions related to Drug cost and pricing policy issues General discussions related to Healthcare supply chain policy issues General discussions related to 340B Drug Pricing Program policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"H.R. 220: Veterans Infertility Treatment Act of 2025; all provisions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; provisions related to Title VII, Subtitle B H.R. 946: Orphan CURES Act; all provisions H.R. 2214: DRUG Act; all provisions H.R. 4317: PBM Reform Act of 2025; all provisions H.R. 6703: Lower Health Care Premiums for All Americans Act; provisions related to Pharmacy Benefit Management (PBM) S. 864: HELP Copays Act; all provisions S. 882: Patients Before Middlemen Act; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX S. 1862: Orphan CURES Act; all provisions S. 3345: PBM Price Transparency and Accountability Act; all provisions Executive Order: Expanding Access to In Vitro Fertilization; all provisions of the order Executive Order: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; all provisions of the order General discussions related to Pharmacy Benefit Manager (PBM) policy issues General discussions related to Healthcare supply chain policy issues General discussions related to Drug cost and pricing policy issues General discussions related to caregiving support and awareness policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; relating to Title VII, Subtitle B H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.; all provisions S. 832: EPIC Act of 2025; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX General discussions related to Drug cost and pricing policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.R. 3838: Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care H.R. 6797: Bipartisan IVF for Military Families Act; all provisions S. 1071: National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care S. 2296: National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care Discussions related to Military access to infertility care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"General discussions related to Biopharmaceutical innovation and patent policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":137213,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139330,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BORCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143811,"prefix":"ms","prefix_display":"MS.","first_name":"MALLORI","nickname":null,"middle_name":"ANNE","last_name":"MERANDINO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Discussions related to tariffs and trade - Section 232 and Section 301 Discussions related to critical mineral access","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23533,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"NICHOLS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151960,"prefix":null,"prefix_display":null,"first_name":"MARY","nickname":null,"middle_name":"BETH","last_name":"SPENCER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"MERCK PTE. LTD.","contribution":"10000.00","ownership_percentage":"0.00","address":"2 Science Park Drive #05-01/12","city":"Ascent 11822","state":null,"state_display":null,"country":"SG","country_display":"Singapore","ppb_city":"Ascent 11822","ppb_state":null,"ppb_state_display":null,"ppb_country":"SG","ppb_country_display":"Singapore"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a7cc7c58-9db4-4dd6-bd82-3ab44ce39165/","filing_uuid":"a7cc7c58-9db4-4dd6-bd82-3ab44ce39165","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a7cc7c58-9db4-4dd6-bd82-3ab44ce39165/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"E. Ashley Hoy","dt_posted":"2026-04-20T19:48:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"975 F Street NW","registrant_address_2":"Suite 400 B","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":308775,"url":"https://lda.gov/api/v1/registrants/308775/","house_registrant_id":38429,"name":"MONUMENT ADVOCACY","description":"Government affairs and strategic consulting services","address_1":"975 F St NW","address_2":"Suite 400B","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"E. ASHLEY HOY","contact_telephone":"+1 202-719-9999","dt_updated":"2026-07-27T17:18:39.228569-04:00"},"client":{"id":182857,"url":"https://lda.gov/api/v1/clients/182857/","client_id":1001196,"name":"PHRMA","general_description":null,"client_government_entity":false,"client_self_select":null,"state":null,"state_display":null,"country":"","country_display":"* Undetermined","ppb_state":null,"ppb_state_display":null,"ppb_country":"","ppb_country_display":"* Undetermined","effective_date":"2007-08-09"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to intellectual property protection, enforcement, and market access within trade negotiations; supply chain management; China; Issues related to global health; and issues related to tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":56188,"prefix":null,"prefix_display":null,"first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"ELLIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":45392,"prefix":null,"prefix_display":null,"first_name":"RICH","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"Issues related to intellectual property protection, enforcement, and market access within trade negotiations; supply chain management; China; issues related to global health; and issues related to tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45392,"prefix":null,"prefix_display":null,"first_name":"RICH","nickname":null,"middle_name":null,"last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":56188,"prefix":null,"prefix_display":null,"first_name":"KIMBERLY","nickname":null,"middle_name":null,"last_name":"ELLIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Medicare Part D, Medicare Part B Issues, Importation of Drugs; H.R. 1, the One Big Beautiful Bill Act; H.R. 1492, S. 832, the EPIC Act; Medicare IRA implementation, Drug Premium Stabilization Program. Drug pricing, reimbursement and coverage related to MFN including CMMI models, 340B, IRA maximum fair price, ASP. PBM Reform included in H.R. 7194, the Consolidated Appropriations Act, the Department of Labor proposed PBM rule. Affordability and patient access issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153017,"prefix":null,"prefix_display":null,"first_name":"JOEL","nickname":null,"middle_name":null,"last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":"Staff Director, Ways & Means Health Subcommittee; L.A. for Rep. Jim Greenwood; L.A. for Rep. Chris Shays","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/686f4086-b88d-4ee6-a108-1afff55476ba/","filing_uuid":"686f4086-b88d-4ee6-a108-1afff55476ba","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/686f4086-b88d-4ee6-a108-1afff55476ba/print/","filing_document_content_type":"text/html","income":null,"expenses":"940000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Aaron Cohen","dt_posted":"2026-04-20T20:58:01-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"6027 Edgewood Bend Court","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105485,"url":"https://lda.gov/api/v1/registrants/401105485/","house_registrant_id":null,"name":"NEUROCRINE BIOSCIENCES, INC","description":"Drug discovery and development","address_1":"6027 Edgewood Bend Court","address_2":null,"address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"FREDERICK DOMBO","contact_telephone":"+1 202-887-1485","dt_updated":"2026-07-30T11:04:36.757386-04:00"},"client":{"id":203759,"url":"https://lda.gov/api/v1/clients/203759/","client_id":12,"name":"NEUROCRINE BIOSCIENCES, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-09-01"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2c5d0123-1385-41b5-aa02-7303db5efcbf/","filing_uuid":"2c5d0123-1385-41b5-aa02-7303db5efcbf","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/2c5d0123-1385-41b5-aa02-7303db5efcbf/print/","filing_document_content_type":"text/html","income":null,"expenses":"1640000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-04-20T21:36:54-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #480","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (P.L. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75), Provisions related to the pharmaceutical industry. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: H.R. 1492, Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025. To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Section 340B Public Health Services Act 340B engagement and MFN related engagement Provisions related to the 340B program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Biopharmaceutical innovation and pricing issues HR 5509, Safe Step Act, Provisions related step therapy protocols Tariff and MFN issues VICP Bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7df25647-6bf3-42d5-82b4-02ab771fc1ce/","filing_uuid":"7df25647-6bf3-42d5-82b4-02ab771fc1ce","filing_type":"2T","filing_type_display":"2nd Quarter - Termination","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7df25647-6bf3-42d5-82b4-02ab771fc1ce/print/","filing_document_content_type":"text/html","income":"5250.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Karen R. Harned","dt_posted":"2026-06-28T16:49:28-04:00","termination_date":"2026-06-23","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1506 Woodacre Drive","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"McLean","registrant_state":"VA","registrant_zip":"22101","registrant":{"id":401107499,"url":"https://lda.gov/api/v1/registrants/401107499/","house_registrant_id":56038,"name":"HARNED STRATEGIES LLC","description":null,"address_1":"1506 Woodacre Drive","address_2":null,"address_3":null,"address_4":null,"city":"McLean","state":"VA","state_display":"Virginia","zip":"22101","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KAREN R HARNED","contact_telephone":"+1 202-886-4651","dt_updated":"2026-09-26T14:42:28.625406-04:00"},"client":{"id":55813,"url":"https://lda.gov/api/v1/clients/55813/","client_id":55813,"name":"JOB CREATORS NETWORK","general_description":"advocacy organization for small business","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-04-04"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support passage of H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Supported Mike Johnson for Speaker of the House. Support passage of H.R. 4178, the Enforce the Caps Act, which would extend federal spending caps through fiscal year 2029. Support H.R. 4, the Rescissions Act of 2025, which would help cut government spending. Support H.R. 3174, the Made in America Manufacturing Finance Act, which would expand access to credit for American manufacturers under the Small Business Administrations 7(a) and 504 loan program. Support H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, which provided a clean continuing resolution to extend funding through January 30, 2026, and also included full-year appropriations for several key departments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"Support Federal Education Freedom Scholarships","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Supported S. 832, the Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025,\" bipartisan, bicameral legislation that fixes the Inflation Reduction Act's small molecule pill penalty to ensure continued R&D investments into small molecule medicines. Support H.R. 5256, 340B ACCESS Act to reform the 340B drug pricing program. Oppose extending the Affordable Care Act subsidies. Support H.R.6703 - Lower Health Care Premiums for All Americans Act designed to cut health costs by, among other things, expanding Association Health Plans (AHPs) for small businesses, creating new \"CHOICE\" arrangements for tax-free health spending, allowing stop-loss insurance for employers, increasing PBM transparency, and funding marketplace cost-sharing. Support President Trump's Great American Healthcare Plan.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Supported S. 583/H.R. 1295 Reorganizing Government Act of 2025,\" which seeks to renew and extend the President's authority to propose executive branch reorganization plans until December 2026, for the purpose of modernizing and improve government efficiency. Supported Mike Johnson for Speaker of the House.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support Medicaid work requirements in H.R.1, \"One Big Beautiful Bill Act.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Support United States trade deals with China and the United Kingdom.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SMB","general_issue_code_display":"Small Business","description":"Supported nomination of Kelly Loeffler to serve as Administrator of the Small Business Administration. Supported H.R. 1199/S.695, the Small Business Investment Act of 2025,\" which would dramatically increase private sector investment in American small businesses by rewarding investors for supporting small business. Supported S. 495 /H.R. 1163, the \"Prove It Act,\" which seeks to reduce burdensome regulations for small businesses by empowering them to petition federal agencies to review proposed regulations that impact small businesses.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Support extending the provisions in the 2017 Tax Cuts and Jobs Act, as set forth in H.R. 1, the \"One Big Beautiful Bill Act.\" Support additional reductions to small business tax rates.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOU","general_issue_code_display":"Housing","description":"Support H.R. 6644, the Housing for the 21st Century Act, which would help boost housing supply and affordability by modernizing federal programs, streamlining regulations, and encouraging local innovation. Among other things it would update FHA loans, reform the HOME program, and support zoning reform, while aiming to reduce building costs and complexity for developers and local governments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Support H.R.5267 - American Franchise Act, which would clarify that franchisors are only joint employers if they possess and exercise substantial and immediate control over essential terms and conditions of employment, like hiring workers, firing workers, setting wages, and disciplinary action.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"Supported national food labeling standards","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"UNM","general_issue_code_display":"Unemployment","description":"Supported H.R. 1156 - the \"Pandemic Unemployment Fraud Enforcement Act,\" which would extend the statute of limitations for combatting and prosecuting the theft of COVID-era unemployment benefits, giving more time for law enforcement to complete current cases, open new ones and recoup billions of taxpayer dollars. Supported S. 4016, the \"Stop Unemployment Fraud Act,\" which would bolster the integrity in the unemployment insurance system by strengthening identify verification and fraud detection measures. Among other thigs it would require states to use advanced data matching and restrict benefit payments until applicant eligibility is confirmed.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Support H.R. 5371 - Continuing Appropriations and Extensions Act, 2026 Supported S. 100/H.R. 425, the Repealing Big Brother Overreach Act, which would repeal the Corporate Transparency Act. Support Small Business Investment Act as included in H.R. 1. Support reforms that would limit the ability of credit card companies to raise processing fees on small businesses who accept credit cards for payment. Support Investor Accelerator Executive Order to reduce much of the burdensome red tape that often prevents investors and entrepreneurs from making their projects a reality. Support the nomination of Kevin Warsh to serve as the Chairman of the Federal Reserve.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142754,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"HARNED","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/","filing_uuid":"4ebc8da1-b3f2-4f07-89b4-e0518e9bb822","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/print/","filing_document_content_type":"text/html","income":null,"expenses":"47670.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-07-15T11:58:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7c80590e-8829-41cf-a635-db969186403f/","filing_uuid":"7c80590e-8829-41cf-a635-db969186403f","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7c80590e-8829-41cf-a635-db969186403f/print/","filing_document_content_type":"text/html","income":null,"expenses":"180000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Heather Strawn","dt_posted":"2026-07-16T11:11:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Ave NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400426042,"url":"https://lda.gov/api/v1/registrants/400426042/","house_registrant_id":null,"name":"LUNDBECK LLC","description":"Specialty and Central Nervous System Bio-pharmaceutical manufacturing","address_1":"1455 Pennsylvania Ave NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"HEATHER STRAWN","contact_telephone":"+1 202-412-1563","dt_updated":"2026-07-29T13:14:27.156557-04:00"},"client":{"id":190625,"url":"https://lda.gov/api/v1/clients/190625/","client_id":12,"name":"LUNDBECK LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025; H.R. 9504, Tax Exempt Hospital Transparency Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Issues related to DTC advertising regulations Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act Issues pertaining to prior authorization - HR 9396, Prior Authorization Accountability Act Issues pertaining to transparency - HR 9393, Lower Costs, More Transparency Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations Issues pertaining to prior authorization - HR 3514, Improving Seniors Timely Access to Care Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariffs on pharmaceutical products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/67b5714f-7362-43a2-86fd-22759280fe17/","filing_uuid":"67b5714f-7362-43a2-86fd-22759280fe17","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/67b5714f-7362-43a2-86fd-22759280fe17/print/","filing_document_content_type":"text/html","income":null,"expenses":"890000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-07-16T16:09:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #480","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S._____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. ___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act HR 5509, Safe Step Act, Provisions related step therapy protocols H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7391, the Community Health Center Drug Pricing Protection Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First S. 891, Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S.4784, An original bill to authorize appropriations for fiscal year 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes, Provisions related to the pharmaceutical industry. Smucker's VICP bill Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Vaccine policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d2530ae0-1069-40c3-bf80-e9979b5a7e5b/","filing_uuid":"d2530ae0-1069-40c3-bf80-e9979b5a7e5b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d2530ae0-1069-40c3-bf80-e9979b5a7e5b/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2026-07-20T12:29:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-10-07T16:33:47.376828-04:00"},"client":{"id":176429,"url":"https://lda.gov/api/v1/clients/176429/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":"Represents the leading research-based pharmaceutical companies in the US.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":"Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas","new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}